Department of Allergy and Immunology, Royal Children's Hospital, Melbourne, Australia.
Expert Rev Vaccines. 2011 May;10(5):575-88. doi: 10.1586/erv.11.32.
Although meningococcal disease caused by serogroup B remains an important public health concern, a licensed vaccine providing broad protection against this pathogen is not yet available. Advances in genomics have paved the way for the discovery of new vaccine candidates for inclusion into a multicomponent serogroup B vaccine. In this article, we will review recent advances in the development of these vaccines, focussing particularly on one of the 'next generation' MenB vaccines, 4CMenB.
虽然由 B 群脑膜炎奈瑟球菌引起的脑膜炎球菌病仍然是一个重要的公共卫生关注点，但尚未有一种针对这种病原体的、具有广泛保护作用的已许可疫苗。基因组学的进步为发现新的疫苗候选物以纳入多组份 B 群脑膜炎球菌疫苗铺平了道路。本文将综述这些疫苗研发方面的最新进展，重点介绍其中一种“下一代”MenB 疫苗 4CMenB。
